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rehabilitation in 1997. Treatment episodes required a 30
day depression and alcoholism diagnosis-free period. Use
of medications and therapy was examined in the year
after the index diagnosis. Healthcare costs, utilization,
and suicide diagnosis were examined in patients with
depression and alcoholism and patients with depression
alone in the two years after the diagnosis. RESULTS: The
1-year prevalence rate of depression, alcoholism, and
depression with alcoholism in 2000 was: 40 per 1000, 2
per 1000, and 1 per 1000. The percent of persons with
depression and alcoholism receiving psychotherapy, 
alcoholism rehabilitation, alcoholism detoxiﬁcation, 
alcoholism medications, or antidepressant mediations
was 58%, 2%, 3%, 24%, and 79%, respectively. Persons
with depression and alcoholism had much higher outpa-
tient, inpatient, and pharmaceutical mental health and
substance abuse and total costs than persons with depres-
sion alone. Persons with depression and alcoholism had
much higher rates of suicide (11% versus 0.5) and emer-
gency room admissions than persons with depression
alone. CONCLUSION: Providers need to better identify
persons with comorbid alcoholism and depression and
more effective treatment needs to be developed and imple-
mented.
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OBJECTIVE: To examine healthcare utilization for
patients receiving atypical and typical antipsychotic med-
ications. METHODS: This was a retrospective, observa-
tional cohort analysis of a pharmacy and medical claims
database from a southeastern US health plan. The phar-
macy claims of subjects between the ages of 6 and 65
years were retrospectively identiﬁed from the health plan
database. Inclusion criteria included the initiation of a
single antipsychotic agent between July 1, 1999 and Sep-
tember 30, 2000; no antipsychotic medication usage 180
days prior to the index prescription date; and continuous
health plan enrollment for a 6-month period before and
12-month period after the index prescription date. Neg-
ative binomial regression was utilized to compare: 1)
ofﬁce-based outpatient utilization; 2) hospital-based out-
patient utilization; 3) inpatient admission; and 4) emer-
gency room utilization. RESULTS: A total of 469 patients
met initial study criteria. Atypical and typical antipsy-
chotics were prescribed to 384 and 85 patients, respec-
tively. Mean length of therapy (days) for the atypical
cohort was signiﬁcantly longer (136 vs. 80; p < 0.001).
The atypical cohort was signiﬁcantly more adherent to
therapy than the typical cohort (mean medication pos-
session ratio (MPR) = 0.53 vs. 0.24; p < 0.001). After
adjusting for differences in demographics, baseline uti-
lization, MPR, and length of therapy, (atypical N = 305,
typical N = 72), the atypical cohort experienced signiﬁ-
cantly fewer ofﬁce visits (2635 vs. 4249 per 1000 patients
per month [P1000PPM]; p = 0.005), signiﬁcantly fewer
inpatient admissions (197 vs. 511 P1000PPM; p = 0.032),
and signiﬁcantly fewer emergency room visits (124 vs.
354 P1000PPM; p = 0.002). Differences in hospital 
outpatient visits were not statistically signiﬁcant (307 vs.
634 P1000PPM; p > 0.05). CONCLUSIONS: Atypical
antipsychotic users were more adherent and remained 
on therapy longer. In addition, patients using atypical
antipsychotic agents were shown to have lower rates of
healthcare resource utilization. This study conﬁrms
thoughts that there is a relationship between adherence
to medication and use of healthcare resources.
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OBJECTIVES: Depression and weight loss are common
problems in older nursing facility (NF) residents. 
Mirtazapine is among the interventions clinicians use to
prevent weight loss in depressed, frail elderly because it
has been reported to be associated with weight gain. Nev-
ertheless, limited data in weight outcomes of depressed
NF residents are available. Our objective was to examine
changes in weight associated with the use of mirtazapine
compared to other non-TCA antidepressant therapies in
the NF population. METHODS: A retrospective chart
review was conducted for 189 NF residents with new
single-antidepressant treatment regimens with at least 6
months of post-treatment weight data. OLS regression
was performed to assess weight change and percentage
weight change at three months and six months. Mirtaza-
pine-treated subjects served as the controlled group (n =
27). Other factors affecting weight were included as
explanatory variables, such as gender, age, co-morbidi-
ties, baseline weight and relative therapeutic dose.
RESULTS: We found no statistical signiﬁcant differences
in weight change at three months and at six months
between mirtazapine and all non-TCA antidepressants
except ﬂuoxetine which was associated with a gain of
four pounds relative to mirtazapine at three months (p =
0.0482). A hypertension diagnosis was associated with
signiﬁcant weight gains at 3 months (2.2 lbs., p = 0.0439
or +1.7%, p = 0.0361) and at 6 months (3.99 lbs., p =
0.0051 or +3.1%, p = 0.0048). A diagnosis of diabetes
was associated with weight loss at 6 month (-3.6 lbs., p
= 0.0370; -3.1%, p = 0.0187). Baseline weight was asso-
ciated with increased weight loss in women at 6 months
(-0.089 lb (per pound baseline), p = 0.0388). CONCLU-
